Press Releases and News
Burlington, MA- Sept 7th, 2021 RedShift BioAnalytics (RedShiftBio), a company providing next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules, announced the appointment of Amol Chaubal to its Board of Directors. Chaubal is Chief Financial Officer at Waters Corporation, the world’s leading specialty measurement company, which has pioneered chromatography, mass spectrometry, and … “RedShift BioAnalytics Appoints Amol Chaubal, CFO of Waters Corporation, to Board of Directors”
READ MORE
Orders for the company’s AQS3pro platform grew over 500% in the second full year since product
launch, and the company closed a $6.4 million Series D Preferred Stock extension to support
continued aggressive growth in 2021.
A new collaborative study from RedshiftBio (Burlington, MA) and a Major Pharmaceutical Company published in the Journal of Pharmaceutical Sciences provides compelling evidence of the benefits of the award winning AQS3pro, a Microfluidic Modulation Spectroscopy platform from RedShift BioAnalytics, Inc., for the biopharmaceutical industry.
READ MORE
RedShiftBio’s AQS³pro Goes Global With Appointment of Spinco Biotech as Exclusive Indian Distributor
RedShiftBio announced its award winning AQS3pro, based on Microfluidic Modulation Spectroscopy (MMS) technology, is now available in India.
READ MORE
RedShift BioAnalytics, Inc. (RedShiftBio) announced its award winning AQS3pro, based on Microfluidic Modulation Spectroscopy (MMS) technology, is now available in Japan, following the appointment of Primetech as exclusive distributor.
READ MORE
RedShift BioAnalytics, Inc. (RedShiftBio) announces its award winning AQS3pro, based on Microfluidic Modulation Spectroscopy (MMS) technology, is now available in China, following the appointment of Beijing-based Topbiox as exclusive distributor.
READ MORE
Pressure BioSciences, Inc., a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced that the combination of PBI’s patented Pressure Cycling Technology (“PCT”) with RedShiftBio’s proprietary Microfluidic Modulation Spectroscopy (“MMS”) resulted in a powerful new platform for biotherapeutic drug development (“PCT-enhanced MMS”).
READ MORE
RedShift BioAnalytics, Inc. (RedShiftBio), a provider of innovative analytical solutions for protein characterization used in biotherapeutic drug development, is pleased to announce the appointment of Julien Bradley as Chief Executive Officer.
READ MORE
Lisbon Portugal hosted the European PEGS conference. This is the largest European event covering all aspects of protein and antibody engineering. Over 1300 attendees gathered to learn about the latest advances in protein and antibody engineering. This was the second year we showcased the next generation IR-based AQS3pro for secondary structure characterization. During this conference … “The AQS³pro – A Hit For The Second Year Running at PEGS Europe”
READ MORE
The 2020 Well Characterized Biologics and Biological Assays conference has just concluded. The agenda focused on practical advice for ensuring CMC success using characterization strategies. Most attendees we spoke with were interested in exploring alternative technologies to circular dichroism and FTIR for monitoring protein structure changes. We demonstrated the power of IR-based Microfluidic Modulation Spectroscopy … “Accelerating Novel And Complex Modules Towards CMC Success”
READ MORE
